IRIDEX Corporation (IRIX)
Market Cap | 34.42M |
Revenue (ttm) | 57.29M |
Net Income (ttm) | -7.25M |
Shares Out | 16.01M |
EPS (ttm) | -0.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 9,297 |
Open | 2.16 |
Previous Close | 2.16 |
Day's Range | 2.12 - 2.24 |
52-Week Range | 1.96 - 3.49 |
Beta | 1.26 |
Analysts | Hold |
Price Target | 3.00 (+37.87%) |
Earnings Date | May 11, 2023 |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha... [Read more]
Financial Performance
In 2022, IRIDEX's revenue was $56.97 million, an increase of 5.69% compared to the previous year's $53.90 million. Losses were -$7.55 million, 44.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IRIX stock is "Hold" and the 12-month stock price forecast is $3.0.
News

Iridex to Report First Quarter Financial Results on May 11, 2023
MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth

Iridex to Present at the 35th Annual Roth Conference
MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
Five Events at Booth #5

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth

Iridex to Participate in Fireside Chat with Stifel Equity Research
MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022
MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways t...

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Announces Second Quarter 2022 Financial Results
MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022
MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Announces First Quarter 2022 Financial Results
Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex Announces the Appointment of Beverly Huss to its Board of Directors
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex Announces Fourth Quarter and Full Year 2021 Financial Results
Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth

Iridex to Present at the 34th Annual Roth Conference
MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021
Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth

Iridex Announces Third Quarter 2021 Financial Results
Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting
An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021
MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

Iridex to Present at the Lytham Partners Fall 2021 Investor Conference
MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex Stock Gains After Posting Highest Sales Since 2007
Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 mill...

Iridex: Q2 Earnings Insights
Shares of Iridex (NASDAQ:IRIX) moved higher by 1.4% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 145.00% over the past year to $0.09, which ...